Enhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptamer

Basit Öğe Kaydı
dc.authoridBARLAS, Firat Baris/0000-0001-6401-686X
dc.authoridSiyah, Pinar/0000-0003-1192-9416
dc.contributor.authorBarlas, Firat Baris
dc.contributor.authorOlceroglu, Bilge
dc.contributor.authorSeleci, Didem Ag
dc.contributor.authorGumus, Zinar Pinar
dc.contributor.authorSiyah, Pinar
dc.contributor.authorDabbek, Meriam
dc.contributor.authorGarnweitne, Georg
dc.date.accessioned2024-08-31T07:47:45Z
dc.date.available2024-08-31T07:47:45Z
dc.date.issued2024
dc.departmentEge Üniversitesien_US
dc.description.abstractBackground: Cancer remains a formidable global health challenge, currently affecting nearly 20 million individuals worldwide. Due to the absence of universally effective treatments, ongoing research explores diverse strategies to combat this disease. Recent efforts have concentrated on developing combined drug regimens and targeted therapeutic approaches. Objective: This study aimed to investigate the anticancer efficacy of a conjugated drug system, consisting of doxorubicin and cisplatin (Dox-Cis), encapsulated within niosomes and modified with MUC-1 aptamers to enhance biocompatibility and target specific cancer cells. Methods: The chemical structure of the Dox-Cis conjugate was characterized using Fourier Transform Infrared Spectroscopy (FTIR) and Liquid Chromatography Quadrupole Time-of-Flight Mass Spectrometry (LC-Q-TOF/MS). The zeta potential and morphological parameters of the niosomal vesicles were determined through Dynamic Light Scattering (DLS) and Transmission Electron Microscopy (TEM). In vitro assessments of cell viability and apoptosis were conducted on MUC-1 positive HeLa cells and MUC-1 negative U87 cells. Results: The findings confirmed the successful conjugation of Dox and Cis within the niosomes. The Nio/Dox-Cis/MUC-1 formulation demonstrated enhanced efficacy compared to the individual drugs and their unencapsulated combination in both cell lines. Notably, the Nio/Dox-Cis/MUC-1 formulation exhibited greater effectiveness on HeLa cells (38.503 +/- 1.407) than on U87 cells (46.653 +/- 1.297). Conclusion: The study underscores the potential of the Dox-Cis conjugate as a promising strategy for cancer treatment, particularly through platforms that facilitate targeted drug delivery to cancer cells. This targeted approach could lead to more effective and personalized cancer therapies.en_US
dc.description.sponsorshipTurkiye Bilimsel ve Teknolojik Arastirma Kurumuen_US
dc.description.sponsorshipTurkiye Bilimsel ve Teknolojik Arastirma Kurumuen_US
dc.identifier.doi10.1002/cam4.70079
dc.identifier.issn2045-7634
dc.identifier.issue15en_US
dc.identifier.pmid39118454en_US
dc.identifier.scopus2-s2.0-85200903275en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.urihttps://doi.org/10.1002/cam4.70079
dc.identifier.urihttps://hdl.handle.net/11454/104520
dc.identifier.volume13en_US
dc.identifier.wosWOS:001287369000001en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofCancer Medicineen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.snmz20240831_Uen_US
dc.subjectCisplatinen_US
dc.subjectCombine Drugen_US
dc.subjectDoxorubicinen_US
dc.subjectMuc-1en_US
dc.subjectNiosomeen_US
dc.titleEnhancing chemotherapeutic efficacy: Niosome-encapsulated Dox-Cis with MUC-1 aptameren_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu